Merck's HIV Drug: April 2026 FDA Decision Insight

Merck’s (MRK) application for its once-daily HIV combination pill doravirine/islatravir has received FDA acceptance, with regulators establishing April 28, 2026 as the decision date for what could become the first two-drug regimen without integrase inhibitors.

This regulatory submission addresses a substantial gap in HIV treatment by proposing a streamlined regimen that may decrease pill burden and minimize long-term adverse effects for patients maintaining viral suppression on existing therapies.

Key Takeaways

FDA sets April 28, 2026 PDUFA date for Merck HIV combo
First potential two-drug regimen without integrase inhibitor class
Phase 3 trials showed non-inferior efficacy versus standard treatments

Market Context

In the roughly $32 billion global HIV therapeutics market, Merck’s HIV portfolio faces competition from industry leaders Gilead Sciences and ViiV Healthcare ¹. Recent quarters saw the company’s current HIV medications Pifeltro and Delstrigo produce combined revenues exceeding $400 million.

This doravirine/islatravir formulation would stand apart from prevailing three-drug standard-of-care protocols by providing an innovative two-drug strategy that excludes integrase strand transfer inhibitors.

Clinical Development Progress

Two pivotal Phase 3 studies, MK-8591A-051 and MK-8591A-052, provide the 48-week data foundation for the New Drug Application ¹. Each trial established non-inferior efficacy when compared to baseline antiretroviral therapy and bictegravir/emtricitabine/tenofovir alafenamide treatment arms respectively.

More than 1,000 adults with virologically suppressed HIV-1 infection participated in these trials. Safety profiles demonstrated general comparability to established treatments across both investigations.

Management Commentary

“Merck has been at the forefront of HIV research for more than 35 years and we are pleased to continue our work to innovate and deliver new options that aim to meet the needs of the HIV community,” said Dr. Eliav Barr, senior vice president of global clinical development at Merck Research Laboratories ¹.

“The health needs of people living with HIV often change over time – whether it’s managing comorbidities or navigating complex medication regimens. We believe DOR/ISL, if approved, will represent an important new complete regimen option designed to help meet their diverse needs.”

Broader HIV Pipeline

Beyond this submission, Merck maintains advancement across multiple HIV development programs. The pharmaceutical company pursues islatravir in partnership with Gilead’s lenacapavir for potential once-weekly oral therapy ¹.

Ongoing Phase 3 investigations encompass treatment-naive patient populations and extension trials assessing long-term safety and efficacy outcomes for the doravirine/islatravir combination.

Regulatory Outlook

FDA acceptance of this application marks an important achievement following earlier regulatory hurdles within islatravir development initiatives. Previous investigations faced temporary suspension due to lymphocyte reduction issues but recommenced after protocol modifications incorporating reduced dosing ².

Upon approval, this combination would equip healthcare providers with an additional option for streamlining HIV treatment protocols while preserving viral suppression effectiveness.

Not investment advice. For informational purposes only.